The International Menopause Society endorses testosterone therapy for postmenopausal women with low sexual desire
GLP-1R antagonist Exendin(939) (Tocris, Ex(939), 50 g/kg, i.v.) or vehicle control was administered 40 min before the onset of coronary ischaemia
In recent years, peptide-based weight-loss drugs, such as GLP-1R agonists and GLP-1R/GIPR dual receptor agonists, have gained widespread global use
8 Novel antidiabetic strategy of BBR and its derivatives BBR has a strong hypoglycemic effect, however its poor oral bioavailability hinders its further clinical application
These are precisely the indications where small molecules have historically delivered some of the most cost-effective therapies, creating a policy paradox: the law designed to reduce drug prices may be diverting innovation away from the most cost-effective modalities